Elicio Therapeutics, Inc. (ELTX) vs INmune Bio, Inc. (INMB)

Elicio Therapeutics, Inc. and INmune Bio, Inc. are both Biotechnology companies. Elicio Therapeutics, Inc. and INmune Bio, Inc. are of similar size ($55.5M and $53.4M). Elicio Therapeutics, Inc. grew revenue faster over the last twelve months: 921.0% against −51.6%. Across the 14 metrics below, INmune Bio, Inc. leads on 8 and Elicio Therapeutics, Inc. on 6.

Valuation

Metric ELTX INMB Biotechnology median
P/E n/m n/m 7.88
P/S 1.23 401.77 11.47
P/B 4.46 2.66 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.78 301.47 10.73
Earnings yield (117.93%) (33.00%) (28.84%)
Free cash flow yield (106.74%) (30.30%) (23.03%)

Profitability

Metric ELTX INMB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (774.56%) (74.82%) (57.72%)
Return on assets (124.36%) (57.08%) (49.22%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric ELTX INMB Biotechnology median
Revenue growth (TTM) 921.02% (51.61%) 5.64%
EPS growth (last fiscal year) 39.29% 11.85% —
Revenue growth, 5-year CAGR — 35.37% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ELTX INMB Biotechnology median
Debt to equity 1.20 0.00 0.00
Current ratio 2.77 4.04 4.73
Net debt to EBITDA 0.25 0.52 0.96

Dividend

Metric ELTX INMB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ELTX INMB Biotechnology median
Market cap 53.35m 55.51m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack